BiotechTube
Home/Nanexa AB/Fredrik Öberg
FÖ

Fredrik Öberg

Chief Scientific Officer

Nanexa AB

Therapeutic Areas

OncologyHematology

Nanexa AB Pipeline

DrugIndicationPhase
NEX-20 (azacitidine)Myelodysplastic Syndromes (MDS)Phase 1
NEX-22Undisclosed oncology targetPreclinical

Leadership Team at Nanexa AB

DW
David Westberg
Chief Executive Officer
AB
Anders Bull
Chief Financial Officer
GA
Göran Ando
Chairman of the Board
JH
Johan Hjertqvist
Board Member
LS
Lena Söderström
Board Member
MG
Michaela Gertz
Board Member
MV
Martin Vidaeus
Head of Business Development
View full Nanexa AB profile